BERTILIMUMAB

BERTILIMUMAB

Bertilimumab is a first-in-class human monoclonal antibody that targets and lowers eotaxin-1 levels. Eotaxin-1 is a chemokine that attracts eosiniphils to sites of inflamation - thus by blocking eotaxin-1, bertilimumab may reduce eosinophile migration or activation and thus provide a benefit to patients suffering from a variety of immunologic and inflammatory diseases. To date, bertilimumab has been well tolerated, with over 100 subjects having received bertilimumab in clinical trials, and has shown promising signs of activity in patients with moderate-to-severe bullous pemphigoid, a rare skin blistering disease. Read More 

Latest News

PRESS RELEASE January 10, 2018

Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018 | Read more 

 

PRESS RELEASE January 4, 2018

Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018 | Read more 

 

PRESS RELEASE December 11, 2017

Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development | Read more 

 

See All News 

Upcoming Events

No upcoming events found

See All Events